A Review Discussing Elotuzumab and its Use in the Second-Line Plus Treatment of Multiple Myeloma

References

• Kumar SK , RajkumarSV, DispenzieriAet al. Improved survival in multiple myeloma and the impact of novel therapies. Blood111(5), 2516–2520 (2008).
   PubMed Web of Science ®Google Scholar
• Kumar SK , DispenzieriA, LacyMQet al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia28(5), 1122–1128 (2014).
   PubMed Web of Science ®Google Scholar
• Boudreault JS , TouzeauC, MoreauP. Triplet combinations in relapsed/refractory myeloma: update on recent Phase III trials. Expert Rev. Hematol.10(3), 207–215 (2017).
   PubMed Web of Science ®Google Scholar
• Kumar SK , DimopoulosMA, KastritisEet al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia31(11), 2443–2448 (2017).
   PubMed Web of Science ®Google Scholar
• Keats JJ , ChesiM, EganJBet al. Clonal competition with alternating dominance in multiple myeloma. Blood120(5), 1067–1076 (2012).
   PubMed Web of Science ®Google Scholar
• Egan JB , ShiC-X, TembeWet al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood120(5), 1060–1066 (2012).
   PubMed Web of Science ®Google Scholar
• Bolli N , Avet-LoiseauH, WedgeDCet al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat. Commun.5, 2997 (2014).
   PubMed Web of Science ®Google Scholar
• Pavanello F , ZuccaE, GhielminiM. Rituximab: 13 open questions after 20 years of clinical use. Cancer Treat. Rev.53, 38–46 (2017).
   PubMed Web of Science ®Google Scholar
• Green DJ , BensingerWI. A View from the plateau: is there a role for allogeneic stem cell transplantation in the era of highly effective therapies for multiple myeloma?Curr. Hematol. Malig. Rep.12(1), 61–67 (2017).
   PubMed Web of Science ®Google Scholar
• Pratt G , GoodyearO, MossP. Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Hematol.138(5), 563–579 (2007).
   PubMed Web of Science ®Google Scholar
• Romano A , ConticelloC, CavalliM. Immunological dysregulation in multiple myeloma microenvironment. Biomed. Res. Int. 2014, 198539 (2014).
   Web of Science ®Google Scholar
• Rawstron AC , DaviesFE, OwenRGet al. B-lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors. Br. J. Hematol.100(1), 176–183 (1998).
   PubMed Web of Science ®Google Scholar
• Koike M , SekigawaI, OkadaMet al. Relationship between CD4(+)/CD8(+) T cell ratio and T activation in multiple myeloma: reference to IL-16. Leuk. Res.26(8), 705–711 (2002).
   PubMed Web of Science ®Google Scholar
• Ogawara H , HandaH, YamazakiTet al. High Th1/Th2 ratio in patients with multiple myeloma. Leuk. Res.29(2), 135–140 (2005).
   PubMed Web of Science ®Google Scholar
• Brown RD , PopeB, MurrayAet al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7–1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta 1 and interleukin-10. Blood98(10), 2992–2998 (2001).
   PubMed Web of Science ®Google Scholar
• Ratta M , FagnoniF, CurtiAet al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood100(1), 230–237 (2002).
   PubMed Web of Science ®Google Scholar
• Malek E , de LimaM, LetterioJJet al. Myeloid-derived suppressor cells: the green light for myeloma immune escape. Blood Rev.30(5), 341–348 (2016).
   PubMed Web of Science ®Google Scholar
• Giallongo C , TibulloD, ParrinnelloNLet al. Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC). Oncotarget7(52), 85764–85775 (2016).
   PubMedGoogle Scholar
• Vivier E , TomaselloE, BaratinMet al. Functions of natural killer cells. Nat. Immunol.9(5), 503–510 (2008).
   PubMed Web of Science ®Google Scholar
• Benson DM Jr , BakanCE, MishraA. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood116(3), 2286–2294 (2010).
   PubMedGoogle Scholar
• Ponzetta A , BenigniG, AntonangeliFet al. Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment. Cancer Res.75(22), 4766–4777 (2015).
   PubMed Web of Science ®Google Scholar
• Pessoa de Magalhaes RJ , VidrialesM-B, PaivaBet al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica98(1), 79–86 (2012).
   PubMed Web of Science ®Google Scholar
• Neri P , BahlisNJ, LonialS. New strategies in multiple myeloma: immunotherapy as a novel approach to treat patients with multiple myeloma. Clin. Cancer Res.22(24), 5959–5965 (2016).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Otero P , PaivaB, EngelhardtMet al. Is immunotherapy here to stay in multiple myeloma? Haematologica 102(3), 423–432 (2017).
   PubMed Web of Science ®Google Scholar
• Boudreault JS , TouzeauC, MoreauP. Triplet combinations in relapsed/refractory myeloma: update on recent Phase III trials. Expert Rev. Hematol.10(3), 207–215 (2017).
   PubMed Web of Science ®Google Scholar
• Veillette A , GuoH. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma. Crit. Rev. Oncol. Hematol.88(1), 167–177 (2013).
   Web of Science ®Google Scholar
• Hsi ED , SteinleR, BalasaBet al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res.14(9), 2775–2784 (2008).
   PubMed Web of Science ®Google Scholar
• Tai Y-T , DillonM, SongWet al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood112(4), 1329–1337 (2008).
   PubMed Web of Science ®Google Scholar
• Magen H , MuchtarE. Elotuzumab: the first approved monoclonal antibody for multiple myeloma. Ther. Adv. Hematol.7(4), 187–195 (2016).
   PubMed Web of Science ®Google Scholar
• Perez-Quintero L , RoncagalliR, GuoRet al. EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization. J. Exp. Med.211(4), 727–742 (2014).
   PubMed Web of Science ®Google Scholar
• Guo H , Cruz-MunozME, WuNet al. Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kynases, CD45, and SHIP-1 that is defective in multiple myeloma cells. Mol. Cell. Biol.35(1), 41–51 (2015).
   PubMed Web of Science ®Google Scholar
• Robertson MJ . Role of chemokines in the biology of natural killer cells. J. Leuk. Biol.71(2), 173–183 (2002).
   PubMed Web of Science ®Google Scholar
• Collins SM . Elotuzumab directly enhances NK cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol. Immunother.62(12), 1841–1849 (2013).
   PubMed Web of Science ®Google Scholar
• Balasa B , YunR, BelmarNAet al. Elotuzumab enhances natural killer activation and myeloma cell killing through interleukin-2 and TNF-α pathways. Cancer Immunol. Immunother.64(1), 61–73 (2015).
   PubMed Web of Science ®Google Scholar
• Van Rhee F , SzmaniaSM, DillonMet al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol. Cancer Ther.8(9), 2616–2624 (2009).
   PubMed Web of Science ®Google Scholar
• Shi J , TricotGJ, GargTKet al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood111(3), 1309–1317 (2008).
   PubMed Web of Science ®Google Scholar
• Bezman NA , JhatakiaA, KearneyAYet al. PD-1 blockade enhances elotuzumab efficacy in mouse tumor models. Blood Adv.1(12), 753–765 (2017).
   PubMed Web of Science ®Google Scholar
• Zonder JA , MohrbacherAF, SinghalSet al. A Phase I, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma. Blood120(3), 552–559 (2012).
   PubMed Web of Science ®Google Scholar
• Gibiansky L , PasseyC, RoyAet al. Model-based pharmacokinetic of elotuzumab in patients with relapsed/refractory multiple myeloma. J. Pharmacokinet. Pharmacodyn.43(3), 243–257 (2016).
   PubMed Web of Science ®Google Scholar
• Lonial S , VijR, HarousseauJ-Let al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J. Clin. Oncol.30(16), 1953–1959 (2012).
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ , BensonDM, BensingerWet al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J. Clin. Oncol.30(16), 1960–1965 (2012).
   PubMed Web of Science ®Google Scholar
• Berdeja J , JagannathS, ZonderJet al. Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a Phase Ib study. Clin. Lymphoma Myeloma Leuk.16(3), 129–138 (2016).
   PubMed Web of Science ®Google Scholar
• Richardson PG , JagannathS, MoreauPet al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, Phase Ib-2 dose-escalation study. Lancet Haematol.2, e516–e527 (2015).
   PubMed Web of Science ®Google Scholar
• Jakubowiak AJ , OffidaniM, PegourieBet al. Randomized Phase II study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM. Blood127(23), 2833–2840 (2016).
   PubMed Web of Science ®Google Scholar
• Mateos M-V , GranellM, OriolAet al. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a Phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma. Br. J. Haematol.175(3), 448–456 (2016)
   PubMed Web of Science ®Google Scholar
• Lonial S , DimopoulosMA, PalumboAet al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med.373, 621–631 (2015).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA , LonialS, WhiteDet al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumor growth. Br. J. Haematol.178(6), 896–905 (2017).
   PubMed Web of Science ®Google Scholar
• Lonial S , DimopoulosMA, WeiselKCet al. Phase III ELOQUENT-2 study: extended four years follow-up of elotuzumab plus lenalidomide/dexamethasone ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM). J. Clin. Oncol.35(Suppl.), Abstract 8028 (2017).
   Google Scholar
• Dimopoulos MA , LonialS, WhiteDet al. Phase 3 ELOQUENT-2 study: extended 4-year follow-up of elotuzumab plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma. Haematologica102(Suppl. 1), Abstract S456 (2017).
   Google Scholar
• Murata K , McCashSI, CarrollBet al. Treatment of multiple myleoma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood. Clin. Biochem.51, 66–71 (2018).
   PubMed Web of Science ®Google Scholar
• Lonial S , RichardsonPG, MateosM-Vet al. ELOQUENT-2 update: phase III study of elotuzumab plus lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma-identifying responders by subset analysis. J. Clin. Oncol.34(15 Suppl.), Abstract 8037 (2016).
   PubMed Web of Science ®Google Scholar
• Liu J , YangH, LiangXet al. Meta-analysis of efficacy of treatments for newly diagnosed and relapsed/refarctory multiple myeloma with del(17p). Oncotarget8(37), 62435–62444 (2017).
   PubMedGoogle Scholar
• Betts K , ChenC, ZichlinMet al. Relative progression-free survival over time of novel triplet regimens for the treatment of relapsed/refractory multiple myeloma. Haematologica102(s1), Abstract E1300 (2017).
   Google Scholar
• Berenson J , MangesR, BadarinathSet al. A Phase II safety study of accelerated elotuzumab infusion, over less than 1 h, in combination with lenalidomide and dexamethasone, in patients with multiple myeloma. Am. J. Hematol.92(5), 460–466 (2017).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA , TerposE, Chanan-KhanAet al. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J. Clin. Oncol.28(33), 4976–4984 (2010).
   PubMed Web of Science ®Google Scholar